The growing and adaptable contract research organisation has unveiled a new distinctive brand identity and website
CatSci, has unveiled a new distinctive brand identity and website, which reflects the broad range of services that the company offers for emerging, mid-sized and large pharma in process research and development.
Including route design and assessment, scale-up and non-GMP material supply to support late-stage lead optimisation through to product launch.
The drug innovation engine is now being driven by emerging pharma. These companies often are not able to carry out process research and development activities in-house; therefore, for them to succeed, collaboration is key.
These organisations and their larger relatives, are turning to commercially-minded CROs, like CatSci, for support through outsourcing to optimise their chemical reactions and create scalable manufacturing processes for their cutting-edge therapeutics.
Since CatSci was formed in 2010 as a spin-out from pharma giant AstraZeneca, the company has evolved from simply an expert catalyst screening provider in response to this changing need in the industry.
CatSci’s refreshed branding reflects how the company has broadened its offerings to provide support for route design and assessment, scale-up and material supply to pharma companies worldwide.
Ross Burn, CEO of CatSci said: “This is the perfect time for us to show how we have evolved to fulfil the demand for a commercially-minded and scientifically-unbiased partner that delivers to the high standards set by pharma. Our focus is to deliver tailored chemistry solutions for drug development that truly enable our customers to create the best therapeutics.”